This article moves us up the healthcare value chain by highlighting the impact that COVID-19 has had on clinical trials. Cutter Consortium Senior Consultant Ben van der Schaaf and Pan Xi describe the current state of mHealth along with technology innovations that forward-looking R&D leaders in pharmaceuticals are deploying. Knowing that the current shift will not be temporary, the authors urge healthcare organizations “to adapt and be in the right place at the right time … to prepare for this imminent change.”
Article
mHealth in Clinical Trials Has Been a Tease for Years; It’s Time to Deliver!
Posted October 8, 2020 | Industry | Leadership | Technology | Amplify
About The Author
Ben van der Schaaf is a Partner at Arthur D. Little, based in New York City. He is an experienced management consultant and advisor to the pharmaceutical industry with an international background in finance and general management. Mr. van der Schaaf focuses on the life sciences and healthcare sector, specifically working in pharmaceutical R&D and commercial operations. His expertise includes post-merger integration, complex program delivery… Read More
Pan Xi is a Management Consultant at Arthur D. Little (ADL), based in Boston, with expertise in the life sciences, consumer goods, and healthcare industries. In the healthcare and biopharmaceutical sectors, Ms. Xi has experience advising clients across clinical development, clinical operations, and quality and compliance. Her recent healthcare projects include the development and implementation of an end-to-end inspection and risk management… Read More
Don’t have a login?
Make one! It’s free and gives you access to all Cutter research.